Russell N. Van Gelder, MD, PhD
Show Description +
Russell N. Van Gelder, MD, PhD, discusses Kiora Pharmaceutical’s novel molecular photoswitch, KIO-301; in the phase 1b trial, treatment provided some visual benefit to patients with extensive vision loss due to retinitis pigmentosa.
Posted: 11/29/2023
Russell N. Van Gelder, MD, PhD
Russell N. Van Gelder, MD, PhD, discusses Kiora Pharmaceutical’s novel molecular photoswitch, KIO-301; in the phase 1b trial, treatment provided some visual benefit to patients with extensive vision loss due to retinitis pigmentosa.
Posted: 11/29/2023
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of AAO: 2023.
Please log in to leave a comment.